Furthermore, IFN-α treatments result in the upregulation of cytotoxic markers such as GrB, perforin, and CD107a, but not the IFN-γ production capacity of peripheral Vγ9Vδ2 T cells in CHC patients (35, 38). The gene discussed is PRF1; the disease is cryohydrocytosis.